

Sunday, 29 May 2016

---

08:00-17:00 Registration

---

08:45-09:00 **S1: Opening Ceremony**

Hall A

Chairs: **Stefan Agewall**, Norway; **Basil S. Lewis**, Israel

---

**Introductions:** Basil S. Lewis, Chairman-Elect, ESC WG on Cardiovascular Pharmacotherapy

**Greetings:**

Stefan Agewall, Chairman, ESC WG on Cardiovascular Pharmacotherapy

Dan Atar, Vice-President, European Society of Cardiology

Michael Glikson, President, Israel Heart Society

Michael Shechter, Chairman, Israel Heart Society WG on Cardiovascular Pharmacotherapy

---

09:00-10:30 **S2: New Challenges in Treatment of Hypertension**

Hall A

Chairs: **Stefan Agewall**, Norway; **Antonio Coca**, Spain; **Yehonatan Sharabi**, Israel

---

*Joint Session with ESC Council on Hypertension*

09:00

**Best Therapy for Resistant Hypertension: The Pathway Study**

Antonio Coca, Dept. of Hypertension & Vascular Risk Unit Hospital Clinic (IDIBAPS). University of Barcelona, Spain

09:20

**Comparing the Results of Pharmacotherapy vs. Device Intervention in Resistant Hypertension**

Sverre Kjeldsen, Dept. of Cardiology, University of Oslo Ullevaal Hospital, Norway

09:40

**When to Start the Treatment of Arterial Hypertension?**

Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Spain

10:00

**The Changing Pattern of Hypertension Treatment: Arterial Properties and Hemodynamics**

Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel

10:20

Q & A

---

10:30-11:00 **Coffee Break, Networking, Exhibition Visit and Posters Viewing**

---

11:00-12:30 **S3: Hot Topics in Heart Failure**

Hall A

Chairs: **Gad Keren**, Israel; **Christian Torp-Pedersen**, Denmark

---

11:00

**Debate: Entresto should be First Line Therapy in HFrEF**

Pro: Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia

Con: Giuseppe M.C. Rosano, Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK

11:25

**Debate: SGLT2 Inhibitors for Type 2 Diabetes Mellitus: Do we need HF Specific Trials?**

Pro: Itamar Raz, Diabetes Unit at Hadassah University Hospital, Jerusalem, Israel

Con: Claudio Ceconi, Dept. of Cardiology, University Hospital of Ferrara, Ferrara, Italy

11:50

**Debate: Beta-Blockers and Digoxin can benefit HFrEF Patients with Atrial Fibrillation**

Pro: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

Con: Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia

12:15

**Obesity in Heart Failure: Update 2016**

Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany

12:30

Light Lunch

<b>13:00-14:00</b>	<b>Satellite 1: Novartis on Heart Failure</b> Chairs: <b>Felipe Martinez</b> , Argentina; <b>Jean Marc Weinstein</b> , Israel	<b>Hall A</b>
13:00	<b>Role of Neprilysin Inhibitors in CV Disease: What can we learn from PARADIGM?</b> <u>Petar Seferovic</u> , Dept. of Cardiology, Belgrade School of Medicine, Serbia	
13:30	<b>Heart Failure Guidelines 2016: What is New?</b> <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
13:45	<b>Panel Discussion: Which Patients and when to use Sacubitril/Valsartan (Entresto)?</b> <u>Offer Amir</u> , <u>Tuvia Ben Gal</u> , <u>Israel Gotsman</u> , <u>Andre Keren</u> , <u>Avi Shotan</u> , Israel	
<b>14:00-15:00</b>	<b>Satellite 2: Boehringer on Diabetes Mellitus</b> Chairs: <b>Avraham Karasik</b> , Israel	<b>Hall A</b>
14:00	<b>Diabetes Therapy: From Glucentric to Complications-Oriented Approach</b> <u>Avraham Karasik</u> , Israel	
14:40	<b>Panel Discussion: Which Patients and when to use Empagliflozin?</b> <u>Rakefet Bacharach</u> , <u>Avraham Karasik</u> , <u>Yoseph Rozenman</u> , Israel	
<b>15:00-16:00</b>	<b>S6: Myocardial and Pericardial Disease: A Case Based Approach to Patient Management</b> Chairs: <b>Yehuda Adler</b> , Israel; <b>Stefan Agewall</b> , Norway; <b>Andre Keren</b> , Israel	<b>Hall A</b>
	<i>Joint Session with ESC Working Group on Myocardial and Pericardial Disease</i>	
15:00	<b>Clinically Suspected Myocarditis with Heart Failure: Treatment? Follow-Up?</b> <u>Shemy Carasso</u> , Baruch Padeh Medical Center, Poriya, Israel	
15:20	<b>Atrial Fibrillation, Treatment with NOAC and Pericarditis: Treatment? Follow-Up?</b> <u>Daniel Monakier</u> , Israel	
15:40	<b>Pericarditis: Treatment? Follow-Up?</b> <u>Dor Lotan</u> , Sheba Medical Center, Tel Hashomer, Israel	
<b>16:00-16:30</b>	<b>Coffee Break, Networking, Exhibition Visit and Posters Viewing</b>	
<b>16:30-18:00</b>	<b>S7: New Directions in Heart Failure</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Stefan Anker</b> , Germany	<b>Hall A</b>
	<i>Joint Session with Heart Failure Association of the ESC</i>	
16:30	<b>Potassium Lowering Drugs</b> <u>Mitja Lainscak</u> , Dept. of Cardiology, General Hospital Celje, Slovenia	
16:50	<b>Iron Therapy</b> <u>Stefan Anker</u> , Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany	
17:10	<b>New Therapies for Acute Decompensated Heart Failure</b> <u>Giuseppe Rosano</u> , Cardiovascular Clinical Group, St. George's Hospital NHS Trust Medical School, London, UK	
17:40	<b>Non-Pharmacologic Therapies for Advanced Heart Failure</b> <u>Offer Amir</u> , Dept. of Cardiology, Baruch Padeh Medical Center, Poriya, Israel	
18:00-19:30	<i>Get Together Cocktails</i>	

Monday, 30 May, 2016

<b>08:00</b>	<b>Registration</b>	
<b>08:30-09:30</b>	<b>S8: Gender Differences in Cardiovascular Pharmacotherapy</b> Chairs: <b>Claudio Ceconi</b> , Italy; <b>Mady Moriel</b> , Israel; <b>Zvi Vered</b> , Israel	<b>Hall A</b>
08:30	<b>Gender Differences in Pharmacology</b> <u>Thomas Walther</u> , Dept. of Pharmacology & Therapeutics, University College Cork, Ireland	
08:45	<b>Gender Differences in Clinical Trials</b> <u>Juan Tamargo</u> , Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain	
09:00	<b>Gender Differences in Cardiovascular Side Effects</b> <u>Giuseppe Rosano</u> , Cardiovascular Clinical Academic Group, St George's Hospital NHS Trust Medical School, London, UK	
09:15	<b>Gender Differences in Treatment Delivery</b> <u>Avital Porter</u> , ICCU and The Women's Cardiac Health Clinic, Rabin Medical Center-Beilinson, and the Sackler Faculty of Medicine, Tel Aviv, Israel	
<b>09:30-10:00</b>	<b>S9: Special Lecture: Breaking News – ESC 2016 Prevention Guidelines</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Yoseph Shemesh</b> , Israel	<b>Hall A</b>
09:30	<b>What is New in the 2016 European ESC Guidelines on Cardiovascular Disease Prevention?</b> <u>Arno W. Hoes</u> , University Medical Center Utrecht, The Netherlands	
<b>10:00-10:30</b>	<b>Coffee Break, Networking, Exhibition Visit and Posters Viewing</b>	
<b>10:30-11:30</b>	<b>S10: Individualizing Antithrombotic Therapy</b> Chairs: <b>L. Buryachkovskaya</b> , Russia; <b>Nikita Lomakin</b> , Russia; <b>Alexander Niessner</b> , Austria	<b>Hall A</b>
	<i>Russian Scientific Inflammation Society, Central Clinical Hospital of the Presidential Department of Russian Federation</i>	
10:30	<b>Laboratory Monitoring of Antiplatelet Therapy</b> <u>Nikita Lomakin</u> , Russia	
10:50	<b>Genetic Aspects of Antithrombotic Therapy</b> <u>Alexey Meshkov</u> , Russia	
11:10	<b>Role of Local Inflammation in the Development of Instent Restenosis</b> <u>Zufar Gabbasov</u> , Russia	
<b>11:30-13:00</b>	<b>S11: Critical Issues in Antithrombotic Therapy: 2016 Update</b> Chairs: <b>Stefan Agewall</b> , Norway; <b>Joao Morais</b> , Portugal; <b>Amit Segev</b> , Israel	<b>Hall A</b>
	(Supported by an Unrestricted Educational Grant from AstraZeneca)	
	<i>Joint Session with ESC Working Group on Thrombosis</i>	
11:30	<b>DAPT Duration after Stenting in Stable CAD</b> <u>Sven Wassmann</u> , Dept. of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany	
11:45	<b>DAPT Duration after Myocardial Infarction</b> <u>Sigrun Halvorsen</u> , Dept. of Cardiology, Oslo University Hospital, Ullevaal, Norway	
12:00	<b>Antithrombotic Therapy in Patients with AF and ACS</b> <u>Dan Atar</u> , Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway	
12:15	<b>Should NOACs Totally replace VKA, Aspirin for Stroke Prevention in AF?</b> <u>Joao Morais</u> , Div. of Cardiology, Santo Andre's Hospital, Leiria, Portugal	
12:30	<b>Reversal Strategies for Non-VK Oral Anticoagulants</b> <u>Alexander Niessner</u> , Dept. of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria	

12:45 Light Lunch

---

**13:30-14:30 Satellite 3: Pfizer on NOACs** **Hall A**  
Chairs: **Basil Lewis**, Israel; **Yoseph Rozenman**, Israel

---

13:30 **Modern Stroke Prevention in Atrial Fibrillation: How to Risk Stratify the Patients? How to Treat the Elderly?**  
Dan Atar, Oslo, Norway

13:50 **The Future of Stroke Prevention in NVAF: NOACs for all ?**  
Roy Beinart, Tel Hashomer, Israel

14:05 **Which NOAC to whom? Translating the Data into Clinical Decisions**  
Michael Glikson, Tel Hashomer, Israel

14:20 **Panel Discussion: Stroke Prevention in NVAF Patients: Challenges in Clinical Practice**

---

**13:30-14:30 Satellite 4: Amgen on Lipid Lowering** **Hall B**  
Chairs: **Yaakov Henkin**, Israel; **Ran Kornowski**, Israel

---

13:30 **New Era in Lipid Lowering Therapy: PCSK9 Inhibitors: Efficacy, Safety and Early Promise of CVD Event Reduction**  
Evan Stein, USA

---

**14:30-16:00 S12: Intersociety Opinion: New Drugs and Therapies** **Hall A**  
Chairs: **Stefan Agewall**, Norway; **Michael Glikson**, Israel; **Felipe Martinez**, Argentina

---

*Joint Session with International Society of Cardiovascular Pharmacotherapy*

14:30 **New Anti-Arrhythmics**  
George Dan, University of Medicine "Carol Davila", Bucharest, Romania

14:50 **New Anti-Thrombotics**  
Antoni Martínez Rubio, Dept. of Cardiology, University Hospital of Sabadell, Barcelona, Spain

15:10 **New Drugs for Angina and CAD**  
Juan Tamarco, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain

15:30 **New Drugs for Heart Failure**  
Felipe A. Martinez, Cordoba National University, Argentina

15:50 Conclusion

---

**14:30-16:00 S13: Focus Session: Temporal Trends, Treatments and Outcomes after ACS in Israel: The Israel National ACSIS Project** **Hall B**  
Chairs: **Zaza Iakobishvili**, Israel; **Ran Kornowski**, Israel

---

*Joint Session with the Israel Heart Society Working Group for Acute Cardiac Care*

14:30 **ACIS 2000-2013: Overview**  
Ilan Goldenberg, Sheba Medical Center and Tel Aviv University, Israel

14:50 **Novel Oral P2Y12 Inhibitors Uptake: Insights from ACSIS 2013 and other Real Life Data**  
Roy Beigel, Israel

15:10 **ACIS 2000-2013: Reperfusion Strategies and Outcomes**  
Eli Lev, Rabin Medical Center and Tel Aviv University, Israel

15:30 **Panel Discussion:** Moshe Flugelman, Israel; Shmuel Gottlieb, Israel; Sigrun Halvorsen, Norway; Nikita Lomakin, Russia; Joao Morais, Portugal; Sven Wassmann, Germany

16:00 Conclusion

## E-Poster Presentations

- 1. The Level of Uric Acid in Metabolic Syndrome Patient and Way of decreasing it**  
Olena Gerasymenko, National University of Pharmacy, Kharkiv, Ukraine
- 2. In Type 2 Diabetics Insulin Therapy is Associated with Micro- But Not Macrovascular Events Independently of Clinical Risk or Coronary Artery Calcium Score – An 8 Year Follow-Up**  
David Halon, Dept. of Cardiovascular Medicine, Lady Davis Carmel Medical Centre and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Israel
- 3. Reckless Administration of QT Interval Prolonging Agents in Elderly Patients with Drug-Induced Torsade De Pointes (TdP)**  
Dan Justo, Internal Medicine and Geriatrics D, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel
- 4. Hypertension and Comorbidity: Reality Clinical Practice Data: Blood Pressure Control**  
Davyd Yakhontov, Novosibirsk Medical University, Russia
- 5. Comparison of Antiplatelet Effects of Different Forms of Acetylsalicylicacid**  
Nikita Lomakin, Central Clinical Hospital of President Department of Russian Federation, Moscow, Russian Federation